Drugs / AHB-171
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07617194 | Jul 2026 → Oct 2027 expected | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07511218 | Apr 2026 → Dec 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07630727 | Jun 2026 → Mar 2029 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-03 | Ausper Biopharma Co., Ltd. | AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 ausperbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AHB-171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630727 ↗ |
| Route | Subcutaneous | “adminstrated via subcutaneous injection” NCT07511218 ↗ |